Table 3 Univariate and multivariate analyses for DFS and OS in patients with stage II–III CCR in cohort 2.
Variable | Disease-free survival (DFS) (n = 167) | Overall survival (OS) (n = 167) | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
HR [95% CI] | P value | HR [95% CI] | P value | HR [95% CI] | P value | HR [95% CI] | P value | |
CINSARC classification (C1/C2) | 3.05 [1.62–5.77] | 2.96 × 10−4 | 3.32 [1.79–6.39] | 1.18 × 10−4 | 3.54 [1.68–7.49] | 4.07 × 10−4 | 2.46 [1.40–4.53] | 1.56 × 10−3 |
TNM stage (II/III) | 2.81 [1.47–5.36] | 1.07 × 10−3 | 2.35 [1.28–4.48] | 5.46 × 10−3 | 1.5 [0.79–2.83] | 2.12 × 10−1 | NA | NA |
MMR status (MSI/MSS) | 1.15 [0.45–2.93] | 7.7 × 10−1 | NA | NA | 0.64 [0.29–1.39] | 2.56 × 10−1 | NA | NA |
Perforation Status | 1.83 [0.65–5.13] | 2.45 × 10−1 | NA | NA | 1.49 [0.46–4.85] | 5.03 × 10−1 | NA | NA |
Tumor Grade | 0.87 [0.21–3.6] | 8.48 × 10−1 | NA | NA | 1.34 [0.41–4.35] | 6.27 × 10−1 | NA | NA |
VELIPI (absence/presence) | 1.62 [0.86–3.07] | 1.33 × 10−1 | NA | NA | 1.7 [0.9–3.32] | 9.78 × 10−2 | NA | NA |
Lymph nodes examined (<12≥) | 0.86 [0.34–2.20] | 7.54 × 10−1 | NA | NA | 1.79 [0.82–3.9] | 1.39 × 10−1 | NA | NA |
CDX2 status (positive/negative) | 3.37 [1.49–7.63] | 1.93 × 10−3 | 3.86 [1.60–8.16] | 4.21 × 10−3 | 3.73 [1.76–7.88] | 2.19 × 10−4 | 2.03 [0.94–3.95] | 6.93 × 10−2 |
